Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.75% |
| 2 | Technology | 13.74% |
| 3 | Healthcare | 12.69% |
| 4 | Industrials | 11.51% |
| 5 | Consumer Discretionary | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
Cameco
CCJ
$42.6B
| $4.07M | 0.01% |
388,500
-1,055,000
| -73% | -$9.53M |
|
1802
KVH Industries
KVHI
$145M
| $4.05M | 0.01% |
343,100
+100,900
| +42% | +$997K |
|
1803
Ceco Environmental
CECO
$4.66B
| $4.05M | 0.01% |
290,183
+117,800
| +68% | +$1.44M |
|
1804
Mannatech
MTEX
$12.1M
| $4.04M | 0.01% |
199,260
+2,900
| +1% | +$51.9K |
|
|
TAHO
1805
DELISTED
Tahoe Resources Inc
TAHO
| $4.04M | 0.01% |
429,651
+411,451
| +2,261% | +$4.29M |
|
|
DEST
1806
DELISTED
Destination Maternity Corporation
DEST
| $4.04M | 0.01% |
781,400
-80,900
| -9% | -$561K |
|
|
TLRD
1807
DELISTED
Tailored Brands, Inc.
TLRD
| $4.03M | 0.01% |
+157,550
| New | +$3.05M |
|
1808
Watts Water Technologies
WTS
$12.8B
| $4.02M | 0.01% |
61,600
+12,100
| +24% | +$792K |
|
1809
German American Bancorp
GABC
$1.93B
| $4.01M | 0.01% |
114,450
+5,100
| +5% | +$154K |
|
1810
Zebra Technologies
ZBRA
$17.8B
| $4.01M | 0.01% |
+46,731
| New | +$3.46M |
|
1811
First Internet Bancorp
INBK
$254M
| $4.01M | 0.01% |
125,200
+72,600
| +138% | +$1.98M |
|
1812
Lakeland Industries
LAKE
$117M
| $4M | 0.01% |
384,802
+5,000
| +1% | +$53K |
|
1813
Sierra Bancorp
BSRR
$532M
| $3.98M | 0.01% |
149,695
-10,405
| -6% | -$220K |
|
1814
Eastern Company
EML
$153M
| $3.98M | 0.01% |
190,300
+4,100
| +2% | +$82.2K |
|
|
MSL
1815
DELISTED
Midsouth Bancorp, Inc.
MSL
| $3.98M | 0.01% |
292,400
+44,200
| +18% | +$510K |
|
1816
Greenlight Captial
GLRE
$514M
| $3.97M | 0.01% |
174,284
+124,084
| +247% | +$2.71M |
|
1817
TriNet
TNET
$3.16B
| $3.97M | 0.01% |
155,100
-213,500
| -58% | -$4.84M |
|
|
MTOR
1818
DELISTED
MERITOR, Inc.
MTOR
| $3.97M | 0.01% |
+319,900
| New | +$3.76M |
|
1819
Orrstown Financial Services
ORRF
$852M
| $3.97M | 0.01% |
177,300
+30,530
| +21% | +$642K |
|
|
FIG
1820
DELISTED
Fortress Investment Group Llc
FIG
| $3.97M | 0.01% |
816,100
+499,700
| +158% | +$2.54M |
|
1821
Seres Therapeutics
MCRB
$45.6M
| $3.96M | 0.01% |
20,015
+5,190
| +35% | +$1.13M |
|
1822
CNO Financial Group
CNO
$5.11B
| $3.96M | 0.01% |
206,900
+149,100
| +258% | +$2.56M |
|
1823
Darling Ingredients
DAR
$10.6B
| $3.96M | 0.01% |
306,315
-608,385
| -67% | -$8.24M |
|
1824
Codexis
CDXS
$171M
| $3.95M | 0.01% |
859,100
-13,100
| -2% | -$61.4K |
|
1825
Motorcar Parts of America
MPAA
$236M
| $3.95M | 0.01% |
146,700
+64,600
| +79% | +$1.7M |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.